The main target for secreted HGF were c-Met on the surface of endothelial cells within the tumor, which indicates that the tumor vasculature mainly responds with the resistance to the sunitinib therapy by a shift to the alternative signaling pathway [64]. Here, HGF is linked to neoplasm.